Immunization of LDL receptor-deficient mice with homologous malondialdehyde-modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 18, Issue 12, 1998, Pages 1972-1982

  Freigang, Stefan ^a   Hörkkö, Sohvi ^a   Miller, Elizabeth ^a   Witztum, Joseph L ^a   Palinski, Wulf ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Arteriosclerosis; Autoantibodies; Immune system; Oxidized lipoproteins; T cells

Indexed keywords

ANTIBODY; AUTOANTIBODY; EPITOPE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MALONALDEHYDE;

ANIMAL CELL; ANTIBODY TITER; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CELL TRANSFORMATION; DRUG EFFECT; DRUG RECEPTOR BINDING; HUMORAL IMMUNITY; IMMUNE SYSTEM; IMMUNIZATION; LIPID OXIDATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 0031702543     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.18.12.1972     Document Type: Article

References (22)

1. Palinski W, Rosenfeld ME, Ylä-Herttuala S, Gurtner GC, Socher SA, Butler S, Parthasarathy S, Carew TE, Steinberg D, Witztum JL. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci USA. 1989;86:1372-1376.
2. Haberland ME, Fong D, Cheng L. Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. Science. 1988;241:215-241.
3. Boyd HC, Gown AM, Wolfbauer G, Chait A. Direct evidence for a protein recognized by a monoclonal antibody against oxidatively modified LDL in atherosclerotic lesions from a Watanabe Heritable Hyperlipidemic rabbit. Am J Pathol. 1989;135:815-826.
4. Rosenfeld ME, Palinski W, Ylä-Herttuala S, Butler S, Witztum JL. Distribution of oxidation-specific lipid-protein adducts and apolipoprotein B in atherosclerotic lesions of varying severity from WHHL rabbits. Arteriosclerosis. 1990;10:336-349.
5. Hammer A, Kager G, Dohr G, Rabl H, Ghassempur I, Jürgens G. Generation, characterization, and histochemical application of monoclonal antibodies selectively recognizing oxidatively modified apoBcontaining serum lipoproteins. Arterioscler Thromb Vase Biol. 1995;15: 704-713.
6. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low density lipoprotein that increase its atherogenicity. N Engl J Med. 1989;320:915-924.
7. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet. 1994; 344:793-795.
8. Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, Watson AD, Lusis AJ. Atherosclerosis: basic mechanisms: oxidation, inflammation, and genetics. Circulation. 1995;91:2488-2496.
9. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malondialdehyde and related aldehydes. Free Radic Biol Chem. 1991;11:81-128.
10. Steinbrecher UP, Fisher M, Witztum JL, Curtiss LK. Immunogenicity of homologous low density lipoprotein after methylation, ethylation, acetylation or carbamylation: generation of antibodies specific for derivatized lysine. J Lipid Res. 1984;25:1109-1116.
11. Curtiss LK, Witztum JL. A novel method for generating region specific monoclonal antibodies to modified proteins: application to the identification of human glucosylated low density lipoproteins. J Clin Invest. 1983;72:1427-1438.
12. Palinski W, Ylä-Herttuala S, Rosenfeld ME, Butler S, Socher SA, Parthasarathy S, Curtiss LK, Witztum JL. Antisera and monoclonal antibodies specific for epitopes generated during the oxidative modification of low density lipoprotein. Arteriosclerosis. 1990;10:325-335.
13. Parums DV, Brown DL, Mitchinson MJ. Serum antibodies to oxidized low-density lipoprotein and ceroid in chronic periaortitis. Arch Pathol Lab Med. 1990;114:383-387.
14. Orekhov AN, Tertov VV, Kabakov AE, Adamova IYu, Pokrovsky SN, Smimov VN. Autoantibodies against modified low density lipoprotein: nonlipid factor of blood plasma that stimulates foam cell formation. Arterioscler Thromb. 1991;11:316-326.
15. Palinski W, Ord V, Plump AS, Breslow JL, Steinberg D, Witztum JL. ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis: demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. Arterioscler Thromb. 1994;14:605-616.
16. Palinski W, Hörkkö S, Miller E, Steinbrecher UP, Powell HC, Curtiss LK, Witztum JL. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apoE-deficient mice: demonstration of epitopes of oxidized low density lipoprotein in human plasma. J Clin Invest. 1996;98:800-814.
17. Witztum JL, Palinski W. Autoimmunity to oxidized lipoproteins. In: Hansson GK, Libby P, eds. Immune Functions of the Vessel Wall. Amsterdam, Netherlands: Harwood Academic Publishers; 1996: 159-172.
18. Salonen JT, Ylä-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R, Nyyssönen K, Palinski W, Witztum JL. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet. 1992;339: 883-887.
19. Maggi E, Finardi G, Poli M, Bollati P, Filipponi M, Stefano PL, Paolini G, Grossi A, Clot P, Albano E, Bellomo G. Specificity of autoantibodies against oxidized LDL as an additional marker for atherosclerotic risk. Coron Artery Dis. 1993;4:1119-1122.
20. Virella G, Virella I, Leman RB, Pryor MB, Lopes-Virella MF. Antioxidized low density lipoprotein antibodies in patients with coronary heart disease and normal healthy volunteers. Int J Clin Lab Res. 1993; 23:95-101.
21. Branch DW, Mitchell MD, Miller E, Palinski W, Witztum JL. Preeclampsia and serum antibodies to oxidised low density lipoprotein. Lancet. 1994;343:645-646.
22. Armstrong VW, Wieland E, Diedrich F, Renner A, Rath W, Kreuzer H, Kuhn W, Oellerich M. Serum antibodies to oxidised low-density lipoprotein in pre-eclampsia and coronary heart disease. Lancet. 1994; 343:1570.